Nadmed, a Helsinki, Finland-based biotech company developing a testing method to measure all four NADs*, raised €3.5M in Series A funding.
The round was led by Nordic Science Investments (NSI) with participation from previous investors Voima Ventures and University of Helsinki Funds, and a grant from Business Finland.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO Jari Närhi, Nadmed offers a testing method to measure all four NADs using fresh blood samples quickly and efficiently with the same accuracy as mass spectrometry. The technology is based on an accurate colorimetric quantification that can be performed even from a minuscule amount of blood. A similar measurement is done for glutathione forms from the same sample.
The company currently serves customers in 27 countries, including clinical laboratories (e.g., Synlab), universities (e.g., Newcastle University), research institutions (e.g., NIH), and pharmaceutical companies (e.g., Clene Nanomedicine).
* NADs are crucial molecules found in every cell of the body, playing a vital role in energy production, cellular repair, and growth, together with glutathiones (an antioxidant in the body). Measuring NAD and glutathione levels is important because imbalances have been reported to be linked to various age-related health conditions, including metabolic disorders, cancer, heart and brain diseases, as well as muscle atrophy.
FinSMEs
22/08/2024